A Phase IIa, randomized, double-blind, placebo-controlled, multi-center study to evaluate the safety, tolerability, and effects of AZP-531, an Unacylated Ghrelin analog, on food-related behavior in patients with Prader-Willi Syndrome

Trial Profile

A Phase IIa, randomized, double-blind, placebo-controlled, multi-center study to evaluate the safety, tolerability, and effects of AZP-531, an Unacylated Ghrelin analog, on food-related behavior in patients with Prader-Willi Syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2016

At a glance

  • Drugs AZP 531 (Primary)
  • Indications Prader-Willi syndrome
  • Focus Adverse reactions
  • Sponsors Alize Pharma
  • Most Recent Events

    • 18 Jul 2016 According to an Alize Pharma media release, the results from this study will be presented at 55th Annual Meeting of the European Society for Paediatric Endocrinology.
    • 18 Jul 2016 According to an Alize Pharma media release, the results from this study will be presented at 9th Conference of the International Prader-Willi Syndrome Organization.
    • 26 Apr 2016 Results will be presented at the International Prader-Willi Syndrome Organisation Conference 2016, according to an Alize Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top